Adjuvanted Influenza Vaccine in Stem Cell Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

August 31, 2016

Conditions
TransplantationInfluenza Vaccines
Interventions
BIOLOGICAL

FLUAD® influenza vaccine

MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.

BIOLOGICAL

FLUVIRAL®

Standard 2015-2016 nonadjuvanted vaccine

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02560909 - Adjuvanted Influenza Vaccine in Stem Cell Transplant | Biotech Hunter | Biotech Hunter